Aurora Cannabis call volume above normal and directionally bullish » 11:4508/1408/14/20
Bullish option flow…
Bullish option flow detected in Aurora Cannabis with 6,207 calls trading, 1.3x expected, and implied vol increasing over 13 points to 163.80%. Aug-20 11 calls and 8/14 weekly 10.5 calls are the most active options, with total volume in those strikes near 1,900 contracts. The Put/Call Ratio is 0.11. Earnings are expected on September 10th.
Alliance Global downgrades Evolution Petroleum to Neutral on Delhi uncertainty » 13:2308/1308/13/20
As previously reported,…
As previously reported, Alliance Global Partners analyst Bhakti Pavani downgraded Evolution Petroleum (EPM) to Neutral from Buy after the operator of the Delhi Field, Denbury Resources (DNR), recently entered into a restructuring support agreement that "significantly increased" the uncertainty and risk for Evolution given that Delhi is its primary asset and accounts for a majority of its revenue. Although Evolution "has a pristine balance sheet and is in strong financial health," Pavani sees a Neutral rating as more appropriate given the uncertainty surrounding the operations at Delhi.
Evolution Petroleum downgraded to Neutral from Buy at Alliance Global Partners » 13:1808/1308/13/20
Alliance Global Partners…
Alliance Global Partners analyst Bhakti Pavani downgraded Evolution Petroleum to Neutral from Buy.
Rising High: An exclusive talk with Cresco Labs co-founder Joe Caltabiano » 11:3808/1308/13/20
CRLBF, APHA, ACB, CVSI, CTST, CGC, CRON, CANN, IGC, TLRY, TCNNF, ZYNE
In this edition of…
Yelp price target raised to $28 from $26 at DA Davidson » 09:2208/1308/13/20
DA Davidson analyst Tom…
DA Davidson analyst Tom Forte raised the firm's price target on Yelp to $28 from $26 and keeps a Buy rating on the shares. The analyst notes his updated discounted cash flow analysis model and also cites a cost-structure-driven margin expansion, continued growth of strategic partnerships, and greater attention on advertisers and business owners as some of the company's potential catalysts.
Groupon price target raised to $36 from $32 at DA Davidson » 09:1508/1308/13/20
DA Davidson analyst Tom…
DA Davidson analyst Tom Forte raised the firm's price target on Groupon to $36 from $32 and keeps a Buy rating on the shares. The analyst notes his updated discounted cash flow analysis model and also cites an improved customer experience, better international results, as well as the reduced conversion gap between mobile and desktop platforms as some of the company's potential catalysts.
Fate Therapeutics price target raised to $40 from $32 at Cantor Fitzgerald » 07:2108/1308/13/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Fate Therapeutics to $40 from $32 and keeps an Overweight rating on the shares. The analyst says Fate continues to make progress dosing patients across many of its programs and remains focused on updates for FT596, FT819, and FT538, where she thinks that the products could be escalated up to efficacious doses relatively quickly.
Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant » 13:5508/1208/12/20
Researchers are looking…
Researchers are looking at their current scientific "toolkit" to see if any potential therapies for other diseases could also help treat patients with COVID-19, and one example of this is a treatment developed by Fate Therapeutics called FT516, which received support in its early stages from a Late Stage Preclinical grant awarded by CIRM, Yimy Villa writes in The Stem Cellar, the official blog of CIRM, or California's Stem Cell Agency. FT516 uses induced pluripotent stem cells, which are a kind of stem cell made from reprogrammed skin or blood cells that have the potential to become any kind of cell in the body. For FT516, iPSCs are transformed into natural killer cells, which are a type of white blood cell that are a vital part of the immune system and play a role in fighting off viral infections, the blog post reads. Prior to the coronavirus pandemic, FT516 was used in a clinical trial to treat patients with acute myeloid leukemia and B-cell lymphoma, which are two different kinds of blood cancer, the author notes, adding that due to the natural ability of NK cells to fight off viruses, it is believed that FT516 may also help play a role in diminishing viral replication of the novel coronavirus in COVID-19 patients.Reference Link
Catalyst Pharmaceuticals price target lowered to $6 from $7 at Piper Sandler » 10:4908/1108/11/20
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Catalyst Pharmaceuticals to $6 from $7 as he has tempered his near- and long-term growth trajectory to account for the last five quarters of Firdapse revenues, including the $29.6M reported for Q2. The company also announced that the Phase 3 trial evaluating Firdapse in MuSK-MG missed the primary endpoint, but Catanzaro noted that this opportunity was excluded from his model and has no impact on his assumptions. Catanzaro keeps an Overweight rating on Catalyst shares.
Groupon price target raised to $27 from $22 at Wedbush » 07:2408/1108/11/20
Wedbush analyst Ygal…
Wedbush analyst Ygal Arounian raised the firm's price target on Groupon to $27 from $22 and keeps a Neutral rating on the shares. The analyst notes that Groupon reported better than expected Q2 results, with revenue benefiting from an acceleration in Goods and EBITDA coming in marginally positive versus his materially negative estimate.